STOCK TITAN

Jade Biosciences: Bellevue reports 6.8% passive stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Jade Biosciences, Inc. (JBIO) is the subject of Amendment No. 2 to a Schedule 13G in which Bellevue Group AG and its wholly owned subsidiary, Bellevue Asset Management AG, jointly report beneficial ownership of 4,293,937 common shares, representing 6.8% of the class. They report shared voting and shared dispositive power over the same 4,293,937 shares, with zero sole voting or dispositive power. The reported percentage uses 63,597,387 common shares outstanding as of August 3, 2026, as reported by Jade Biosciences in its Form 10-Q filed August 10, 2026.

Beneficial ownership 4,293,937 shares Jointly reported by Bellevue Group AG and its wholly owned subsidiary, Bellevue Asset Management AG
Class ownership 6.8% Percentage of Jade Biosciences common stock beneficially owned, based on shares outstanding as of August 3, 2026
Common shares outstanding 63,597,387 shares As of August 3, 2026; basis for the reported ownership percentage
beneficial ownership regulatory
"Amount beneficially owned: 4,293,937"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Shared Voting Power regulatory
"Shared Voting Power 4,293,937.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 4,293,937.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many JBIO shares did Bellevue Group report beneficially owning?

Bellevue Group AG and its wholly owned subsidiary, Bellevue Asset Management AG, jointly reported beneficial ownership of 4,293,937 Jade Biosciences common shares, or 6.8% of the class. They reported shared voting and dispositive power over that position.

What share count underlies Bellevue's reported 6.8% JBIO ownership?

The percentage is based on 63,597,387 Jade Biosciences common shares outstanding as of August 3, 2026, as reported by the company in its Form 10-Q filed August 10, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





008064206

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The percentages of beneficial ownership contained herein are based on 63,597,387 shares of Common Stock outstanding as of August 3, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on August 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The percentages of beneficial ownership contained herein are based on 63,597,387 shares of Common Stock outstanding as of August 3, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on August 10, 2026.


SCHEDULE 13G



Bellevue Group AG
Signature:/s/ Stefano Montalbano
Name/Title:Stefano Montalbano/ Chief Financial Officer
Date:11/16/2026
Signature:/s/ Christoph Eisenring
Name/Title:Christoph Eisenring/ Head Legal & Compliance
Date:11/16/2026
Bellevue Asset Management AG
Signature:/s/ Christoph Eisenring
Name/Title:Christoph Eisenring/ Head Legal & Compliance
Date:11/16/2026
Signature:/s/ Ivo Betschart
Name/Title:Ivo Betschart/Chief Finance & Controlling
Date:11/16/2026

Keep reading